Bank of Montreal Can Decreases Stock Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Bank of Montreal Can lowered its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 59.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 106,349 shares of the company's stock after selling 155,053 shares during the period. Bank of Montreal Can's holdings in Hims & Hers Health were worth $1,890,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Renaissance Technologies LLC grew its position in shares of Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company's stock valued at $121,936,000 after buying an additional 3,205,108 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Hims & Hers Health by 15.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company's stock valued at $30,714,000 after buying an additional 218,566 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Hims & Hers Health by 67.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company's stock valued at $13,701,000 after buying an additional 273,473 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its position in shares of Hims & Hers Health by 164.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company's stock valued at $10,663,000 after buying an additional 328,142 shares during the last quarter. Finally, State of Michigan Retirement System grew its position in shares of Hims & Hers Health by 177.8% in the 2nd quarter. State of Michigan Retirement System now owns 500,000 shares of the company's stock valued at $10,095,000 after buying an additional 320,000 shares during the last quarter. Institutional investors own 63.52% of the company's stock.

Hims & Hers Health Trading Up 8.3 %

HIMS stock traded up $2.63 during trading on Friday, reaching $34.23. 13,423,961 shares of the stock were exchanged, compared to its average volume of 9,906,611. The firm's 50 day moving average is $23.21 and its 200 day moving average is $20.36. Hims & Hers Health, Inc. has a twelve month low of $8.09 and a twelve month high of $35.02. The firm has a market cap of $7.48 billion, a P/E ratio of 76.23 and a beta of 1.25.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company's quarterly revenue was up 77.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.04) earnings per share. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HIMS has been the topic of a number of analyst reports. Bank of America lowered Hims & Hers Health from a "buy" rating to an "underperform" rating and reduced their price target for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. TD Cowen restated a "buy" rating and set a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Piper Sandler restated a "neutral" rating and set a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a research report on Wednesday, November 6th. Finally, Needham & Company LLC initiated coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a "buy" rating and a $24.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $21.43.

Insider Transactions at Hims & Hers Health

In related news, insider Michael Chi sold 2,054 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $33.56, for a total transaction of $68,932.24. Following the completion of the sale, the insider now directly owns 184,947 shares of the company's stock, valued at approximately $6,206,821.32. This trade represents a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Soleil Boughton sold 2,339 shares of the stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $16.50, for a total value of $38,593.50. Following the sale, the insider now directly owns 176,952 shares of the company's stock, valued at $2,919,708. The trade was a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 974,495 shares of company stock valued at $22,548,139 over the last ninety days. 17.71% of the stock is currently owned by insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.